keyword
MENU ▼
Read by QxMD icon Read
search

avogaro

keyword
https://www.readbyqxmd.com/read/29449951/glucagon-like-peptide-1-receptor-agonists-are-not-associated-with-retinal-adverse-events-in-the-fda-adverse-event-reporting-system
#1
Gian Paolo Fadini, Mayur Sarangdhar, Angelo Avogaro
Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely used for the treatment of type 2 diabetes. In large trials, the GLP-1RAs liraglutide and semaglutide improved cardiovascular outcomes, but semaglutide was associated with an increased risk of retinopathy progression. We herein evaluated the association between GLP-1RA and retinal adverse events (AE) in the Food and Drug Administration Adverse Event Reporting System (FAERS). Research design and methods: We mined the FAERS between 2004q1 and 2017q1 (for a total of 9 217 555 AE reports) to analyze disproportionality and evaluate the association between GLP-1RAs and AEs involving the retina...
2018: BMJ Open Diabetes Research & Care
https://www.readbyqxmd.com/read/29438401/systemic-and-vascular-inflammation-in-an-in-vitro-model-of-central-obesity
#2
Arti Ahluwalia, Alessandra Misto, Federico Vozzi, Chiara Magliaro, Giorgio Mattei, Maria Cristina Marescotti, Angelo Avogaro, Elisabetta Iori
Metabolic disorders due to over-nutrition are a major global health problem, often associated with obesity and related morbidities. Obesity is peculiar to humans, as it is associated with lifestyle and diet, and so difficult to reproduce in animal models. Here we describe a model of human central adiposity based on a 3-tissue system consisting of a series of interconnected fluidic modules. Given the causal link between obesity and systemic inflammation, we focused primarily on pro-inflammatory markers, examining the similarities and differences between the 3-tissue model and evidence from human studies in the literature...
2018: PloS One
https://www.readbyqxmd.com/read/29394900/how-to-interpret-the-role-of-sdf-1%C3%AE-on-diabetic-complications-during-therapy-with-dpp-4-inhibitors
#3
EDITORIAL
Gian Paolo Fadini, Angelo Avogaro
No abstract text is available yet for this article.
February 2, 2018: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29377537/counterpoint-to-the-hypothesis-that-sglt2-inhibitors-protects-the-heart-by-antagonizing-leptin
#4
Angelo Avogaro, Gian Paolo Fadini
Galileo Galilei, who was Professor at the University of Padova, taught us one of the foundations of modern science: experimental evidence always supersedes theoretical evidence. As fascinating as a hypothesis can be, it should be backed by solid experimental data and should be verifiable or rebuttable experimentally.
January 27, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29343271/p66shc-gene-expression-in-peripheral-blood-mononuclear-cells-and-progression-of-diabetic-complications
#5
Gian Paolo Fadini, Mattia Albiero, Benedetta Maria Bonora, Nicol Poncina, Saula Vigili de Kreutzenberg, Angelo Avogaro
BACKGROUND: The risk of diabetic complications is modified by genetic and epigenetic factors. p66Shc drives the hyperglycaemic cell damage and its deletion prevents experimental diabetic complications. We herein tested whether p66Shc expression in peripheral blood mononuclear cells (PBMCs) predicts adverse outcomes in people with diabetes. METHODS: In a cohort of 100 patients with diabetes (16 type 1 and 84 type 2), we quantified baseline p66Shc expression in PBMCs by quantitative PCR...
January 17, 2018: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29320602/when-metformin-is-not-enough-pros-and-cons-of-sglt2-and-dpp-4-inhibitors-as-a-second-line-therapy
#6
REVIEW
Angelo Avogaro, Elías Delgado, Ildiko Lingvay
The newer oral therapies for type 2 diabetes mellitus, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors, have advantages over older agents. Dipeptidyl peptidase-4 inhibitors are weight neutral and have few adverse effects. Sodium glucose cotransporter 2 inhibitors have additional benefits: weight loss, blood pressure reduction, cardiovascular risk reduction, and renoprotective effects. Sodium glucose cotransporter 2 inhibitors have increased risk of urogenital infections and possible risk of "euglycaemic" diabetic ketoacidosis...
January 10, 2018: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/29300991/effects-of-hypoglycaemia-on-circulating-stem-and-progenitor-cells-in-diabetic-patients
#7
Gian Paolo Fadini, Federico Boscari, Roberta Cappellari, Silvia Galasso, Mauro Rigato, Benedetta Maria Bonora, Marianna D'Anna, Daniela Bruttomesso, Angelo Avogaro
Context: Iatrogenic hypoglycaemia is the most common acute diabetic complication and it significantly increases morbidity. In people with diabetes, reduction in the levels of circulating stem and progenitor cells predicts adverse outcomes. Objective: To evaluate whether hypoglycaemia in diabetes affects circulating stem cells and endothelial progenitor cells (EPCs). Design: We performed an experimental hypoglycaemia study (study 1) and a case-control study (study 2)...
December 28, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29277378/assessment-of-hypoglycaemia-during-basal-insulin-therapy-temporal-distribution-and-risk-of-events-using-a-predefined-or-an-expanded-definition-of-nocturnal-events
#8
M C Riddle, G B Bolli, A Avogaro, M G Álvarez, A Merino-Trigo, E Boëlle-Le Corfec, P D Home
AIM: To describe in type 2 diabetes the 24-hour distribution of hypoglycaemia and compare the frequency of nocturnal events based on a predefined nocturnal window or an expanded interval, using illustrative data for two insulin glargine formulations. METHODS: Temporal distribution of hypoglycaemic events was assessed descriptively and by profile using participant-level data from three randomized trials comparing insulin glargine 300 U/mL (Gla-300) and 100 U/mL (Gla-100)...
December 11, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29258716/freestyle-libre-and-dexcom-g4-platinum-sensors-accuracy-comparisons-during-two-weeks-of-home-use-and-use-during-experimentally-induced-glucose-excursions
#9
F Boscari, S Galasso, A Facchinetti, M C Marescotti, V Vallone, A M L Amato, A Avogaro, D Bruttomesso
BACKGROUND AND AIMS: This study compared the accuracy of the FreeStyle Libre (Abbott, Alameda, CA) and Dexcom G4 Platinum (DG4P, Dexcom, San Diego, CA) CGM sensors. METHODS AND RESULTS: Twenty-two adults with type 1 diabetes wore the two sensors simultaneously for 2 weeks. Libre was used according to manufacturer-specified lifetime (MSL); DG4P was used 7 days beyond MSL. At a clinical research center (CRC), subjects were randomized to receive the same breakfast with standard insulin bolus (standard) or a delayed and increased (delayed & increased) bolus to induce large glucose swings during weeks 1 and 2; venous glucose was checked every 5-15 min for 6 h...
November 11, 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/29251397/keeping-the-right-track-in-the-treatment-of-patients-with-type-2-diabetes
#10
EDITORIAL
Angelo Avogaro
No abstract text is available yet for this article.
December 18, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29134608/factors-that-may-account-for-cardiovascular-risk-reduction-with-a-dipeptidyl-peptidase-4-inhibitor-vildagliptin-in-young-patients-with-type-2-diabetes-mellitus
#11
Marc Evans, Plamen Kozlovski, Päivi M Paldánius, James E Foley, Vaishali Bhosekar, Carmen Serban, Angelo Avogaro
INTRODUCTION: In a meta-analysis, we observed a significant 37% relative risk reduction in prospectively adjudicated major adverse cardiac events [MACEs, comprising of non-fatal myocardial infarction, non-fatal stroke, cardiovascular (CV) death] with vildagliptin vs. comparators in younger (< 65 years) patients with type 2 diabetes mellitus (T2DM), while the risk was similar in older patients (≥ 65 years). We carried out an exploratory analysis to identify the patient characteristics and on-treatment effects that may have contributed to the different outcomes in the two age groups...
November 13, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29053207/dpp-4-inhibitors-moderate-the-risk-of-genitourinary-tract-infections-associated-with-sglt2-inhibitors
#12
Gian Paolo Fadini, Benedetta Maria Bonora, Mayur Sarangdhar, Mauro Rigato, Angelo Avogaro
Genito-urinary tract infections (GUTI) are the most common adverse event (AE) during therapy with sodium-glucose cotransporter 2 inhibitors (SGLT2i). We evaluated whether dipeptidyl peptidase 4 inhibitors (DPP4i) moderate the risk of GUTI during therapy with SGLT2i, using two approaches. First, we screened the literature for randomized controlled trials (RCTs) directly comparing the frequency of GUTI in patients receiving a DPP4i/SGLT2i combination therapy versus those receiving a SGLT2i only. In the 5 trials we retrieved, the pooled RR for genital tract infections (GTI) in patients on a DPP4i/SGLT2i combination therapy versus those on SGLT2i alone was 0...
October 20, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29017104/shift-of-monocyte-subsets-along-their-continuum-predicts-cardiovascular-outcomes
#13
Roberta Cappellari, Marianna D'Anna, Benedetta Maria Bonora, Mauro Rigato, Andrea Cignarella, Angelo Avogaro, Gian Paolo Fadini
BACKGROUND AND AIMS: Distribution of monocyte subsets has been shown to predict cardiovascular outcomes. However, monocytes form a continuum and categorization into discrete subsets may be an oversimplification. We herein aimed at establishing whether distribution of monocytes based on CD14 and CD16 fluorescence intensity provides incremental and complementary information on cardiovascular outcomes beyond enumeration of traditional subsets. METHODS: A cohort of 227 patients at high cardiovascular risk was characterized at baseline and followed for a median of 4 years...
November 2017: Atherosclerosis
https://www.readbyqxmd.com/read/29016810/mir-30c-5p-regulates-macrophage-mediated-inflammation-and-pro-atherosclerosis-pathways
#14
Giulio Ceolotto, Alessandra Giannella, Mattia Albiero, Maniselvan Kuppusamy, Claudia Radu, Paolo Simioni, Katia Garlaschelli, Andrea Baragetti, Alberico Luigi Catapano, Elisabetta Iori, Gian Paolo Fadini, Angelo Avogaro, Saula Vigili de Kreutzenberg
Aims: Atherosclerosis is an inflammatory disease wherein cholesterol-loaded macrophages play a major role. MicroRNAs and microparticles propagate inflammatory pathways and are involved in cardiovascular disease. We aimed to screen and validate circulating microRNAs correlated with atherosclerosis development in humans, and to dissect the molecular mechanisms associated with atherogenesis using in vitro and in vivo approaches. Methods and results: A panel of 179 secreted microRNAs was screened in plasma samples of patients with and without atherosclerosis, and validated cross-sectionally and prospectively in patients followed for up to 11 years...
November 1, 2017: Cardiovascular Research
https://www.readbyqxmd.com/read/28967594/rationale-and-design-of-the-darwin-t2d-dapagliflozin-real-world-evidence-in-type-2-diabetes-a-multicenter-retrospective-nationwide-italian-study-and-crowdsourcing-opportunity
#15
G P Fadini, G Zatti, A Consoli, E Bonora, G Sesti, A Avogaro
BACKGROUND: Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routinely accumulated clinical data are increasingly valued. AIMS: We herein describe rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes), a multicenter retrospective nationwide study conducted at 50 specialist outpatient clinics in Italy and promoted by the Italian Diabetes Society...
August 8, 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28927403/circulating-levels-and-characterization-of-microparticles-in-patients-with-different-degrees-of-glucose-tolerance
#16
Alessandra Giannella, Claudia Maria Radu, Lorenzo Franco, Elena Campello, Paolo Simioni, Angelo Avogaro, Saula Vigili de Kreutzenberg, Giulio Ceolotto
BACKGROUND: Microparticles (MPs) are vesicular structures shed from endothelial or circulating blood cells, after activation or apoptosis, and can be considered markers of vascular damage. We aimed to determine the levels of circulating MPs, their content of miRNA-126-3p and 5p, and their relationship with early endothelial activation/damage, in patients with different degree of glucose tolerance. METHODS: CD62E(+), CD62P(+), CD142(+), CD45(+) circulating MPs, their apoptotic (AnnexinV(+)) fractions, and miRNA-126 expression were determined in 39 prediabetic (PreDM), 68 type 2 diabetic (T2DM), and 53 control (NGT) subjects, along with main anthropometric and biochemical measurements...
September 19, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28802220/comparison-of-lower-limb-muscle-strength-between-diabetic-neuropathic-and-healthy-subjects-using-opensim
#17
Alessandra Scarton, Ilse Jonkers, Annamaria Guiotto, Fabiola Spolaor, Gabriella Guarneri, Angelo Avogaro, Claudio Cobelli, Zimi Sawacha
Diabetes neuropathy and vasculopathy are the two major complications of diabetes mellitus, leading to diabetic foot disease, of which the worst consequences are plantar ulcers and amputations. Motor impairments like joint stiffness and loss of balance are distinctive effects of diabetes and they have been extensively explored. However, while altered muscle function has been also assessed through experimentally measured surface electromyography, little is known about muscle forces. The objective of this study was to estimate muscle forces in subjects with diabetes and to use these data to identify differences with respect to a population of healthy subjects matched for age and BMI...
October 2017: Gait & Posture
https://www.readbyqxmd.com/read/28666360/overnight-closed-loop-control-improves-glycemic-control-in-a-multicenter-study-of-adults-with-type-1-diabetes
#18
RANDOMIZED CONTROLLED TRIAL
Sue A Brown, Marc D Breton, Stacey M Anderson, Laura Kollar, Patrick Keith-Hynes, Carol J Levy, David W Lam, Camilla Levister, Nihat Baysal, Yogish C Kudva, Ananda Basu, Vikash Dadlani, Ling Hinshaw, Shelly McCrady-Spitzer, Daniela Bruttomesso, Roberto Visentin, Silvia Galasso, Simone Del Favero, Yenny Leal, Federico Boscari, Angelo Avogaro, Claudio Cobelli, Boris P Kovatchev
Context: Closed-loop control (CLC) for the management of type 1 diabetes (T1D) is a novel method for optimizing glucose control, and strategies for individualized implementation are being developed. Objective: To analyze glycemic control in an overnight CLC system designed to "reset" the patient to near-normal glycemic targets every morning. Design: Randomized, crossover, multicenter clinical trial. Participants: Forty-four subjects with T1D requiring insulin pump therapy...
October 1, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28605281/re-plasminogen-activator-inhibitor-1-and-pericardial-fat-in-individuals-with-type-2-diabetes-mellitus-by-bayomi-et-al-metab-syndr-relat-disord-2017-15-269-275
#19
Angelo Avogaro
Plasminogen activator inhibitor-1 (PAI-1) is a member of the serine protease inhibitor (serpin) superfamily, which inactivates tissue plasminogen activator (tPA); therefore, increased level of PAI-1 antigen counteracts the anticoagulant effect of tPA and facilitates the fibrin clot formation. Plasma PAI-1 antigen and activity levels are associated with increased body mass index and with features of the insulin resistance syndrome like obesity and diabetes. Visceral adipose tissue produces more PAI-1 than subcutaneous adipose tissue: This increased production of PAI-1 from the visceral adipose tissue is one important link between visceral obesity and cardiovascular disease...
August 2017: Metabolic Syndrome and related Disorders
https://www.readbyqxmd.com/read/28589447/cognitive-neurophysiologic-and-metabolic-sequelae-of-previous-hypoglycemic-coma-revealed-by-hyperinsulinemic-hypoglycemic-clamp-in-type-1-diabetic-patients
#20
Alberto Maran, Cristina Crepaldi, Franco Del Piccolo, Ian Macdonald, Lisa Zarantonello, Angelo Avogaro, Piero Amodio
To examine the relationship between electroencephalographic (EEG) activity and hypoglycemia unawareness, we investigated early parameters of vigilance and awareness of various symptom categories in response to hypoglycemia in intensively treated type 1 diabetic (T1DM) patients with different degrees of hypoglycemia unawareness. Hypoglycemia was induced with a hyperinsulinemic-hypoglycemic clamp in six T1DM patients with a history of hypoglycemia unawareness previous severe hypoglycemic coma (SH) and in six T1DM patients without (C) history of hypoglycemia unawareness previous severe hypoglycemic coma...
June 6, 2017: Metabolic Brain Disease
keyword
keyword
94325
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"